Sm4 |
Catalog No.GC26424
One-Click Copy Product Info
|
Sm4 is a SOX18 inhibitor (IC₅₀=5.2μM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 365542-77-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Sm4 is a SOX18 inhibitor (IC₅₀=5.2μM)[1]. Sm4 directly targets the SOX18 HMG domain and preferentially disrupts the interaction between SOX18 and its specific binding partners. Sm4 can be used in research related to tumor metastasis and vascular cancers[2-3].
In vitro, treatment of non-small cell lung cancer cell lines (LXF-289 and SK-MES-1) with Sm4 (10-20μM) for 72 hours induced S-phase cell cycle arrest and upregulated p21 expression[4]. Treatment of human dermal lymphatic endothelial cells (HDLEC) and lymphangiosarcoma cells (MO-LAS) with Sm4 (78-156μM) for 24 hours. Sm4 significantly inhibited the expression of SOX18 at both mRNA and protein levels, while downregulating key lymphatic phenotypic markers (Prox1, Flt4, Lyve1) and impeding cell migration and proliferation[5].
In vivo, nude mice subcutaneously implanted with infantile hemangioma stem cells pretreated with Sm4 (10μM) for 24 hours were orally administered Sm4 (25mg/kg) once daily for 7 days. Sm4 significantly reduced the total vascular density and human CD31-positive vascular density in the implants, without affecting the body weight or blood glucose levels of the mice[6]. NSG mice subcutaneously implanted with a mixture of KSHV-infected lymphatic endothelial progenitor cells (K-ECFCLYs) and KSHV-infected lymphatic endothelial cells (K-LECs) were orally administered Sm4 (25mg/kg) once daily for 10 days. Sm4 significantly decreased the KSHV genome copy numbers within the grafted tissue and reduced the spindle cell morphology[7].
References:
[1] Mathias FRANCOIS. Inhibitors of sox18 protein activity for treating angiogenesis- and/or lymphangiogenesis-related diseases. Patent, WO2018112545A1.
[2] Mei J, Yang K, Zhang X, et al. Intratumoral Collagen Deposition Supports Angiogenesis Suggesting Anti-angiogenic Therapy in Armored and Cold Tumors. Adv Sci (Weinh). 2025 Mar;12(10):e2409147.
[3] Kim I, Koh GY. Taking aim at Sox18. Elife. 2017 Jan 31;6:e24238. doi: 10.7554/eLife.24238.
[4] Rodak O, Mrozowska M, Rusak A, et al. Targeting SOX18 Transcription Factor Activity by Small-Molecule Inhibitor Sm4 in Non-Small Lung Cancer Cell Lines. Int J Mol Sci. 2023 Jul 11;24(14):11316.
[5] Koll KK, Zimmermann MM, Will PA, et al. The Transcription Factor SOX18 Inhibitor Small Molecule 4 Is a Potential Treatment of Cancer-Induced Lymphatic Metastasis and Lymphangiosarcoma. Cancer Rep (Hoboken). 2025 Jan;8(1):e70110.
[6] Seebauer CT, Graus MS, Huang L, et al. Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. J Clin Invest. 2022 Feb 1;132(3):e151109.
[7] Tuohinto K, DiMaio TA, Kiss EA, et al. KSHV infection of endothelial precursor cells with lymphatic characteristics as a novel model for translational Kaposi's sarcoma studies. PLoS Pathog. 2023 Jan 23;19(1):e1010753.
| Cell experiment [1]: | |
Cell lines | LXF-289 (human lung adenocarcinoma cell line) and SK-MES-1 (human lung squamous cell carcinoma cell line) |
Preparation Method | Cells were cultured in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% fetal bovine serum, HEPES, L-glutamine, sodium pyruvate, non-essential amino acids, penicillin, and streptomycin at 37°C in a humidified incubator with 5% CO₂. Cells were treated with Sm4 (10-20μM) using two protocols: (i) a single addition 24 hours after plating, or (ii) media replacement with the inhibitor every 24 hours, for a total incubation of 72 hours. |
Reaction Conditions | 10-20μM; 72 hours. |
Applications | Sm4 treatment induced cytotoxic effects in a time- and concentration-dependent manner. It led to S-phase cell accumulation, with a complete disappearance of the G2/M population in LXF-289 cells at 20μM. Treatment upregulated the gene and protein expression of p21, a key regulator of the S-to-G2/M transition. While Sm4 increased SOX17 gene expression, it did not alter SOX7 or SOX17 protein levels. The inhibitor also caused alterations in the expression of cyclins involved in cell cycle regulation. |
| Animal experiment [2]: | |
Animal models | NSG (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ) mice |
Preparation Method | A mixture of KSHV-infected lymphatic endothelial colony-forming cells (K-ECFCLYs, 90-95%) and KSHV-infected lymphatic endothelial cells (K-LECs, 5-10%) was implanted subcutaneously. One day after implantation, Sm4 (25mg/kg) or vehicle was administered. |
Dosage form | 25mg/kg; oral gavage; once daily for 10 sequential days. |
Applications | Sm4 treatment led to the appearance of necrotic areas in the grafts, significantly reduced GFP signal intensity and the area of cells with spindling morphology, and significantly decreased the relative KSHV genome copy numbers in the implanted tissue. |
References: | |
| Cas No. | 365542-77-4 | SDF | |
| Canonical SMILES | O=C(C1=C(C=CC=C1O)CCC2=CC=C3C=CC=CC3=C2)O | ||
| Formula | C19H16O3 | M.Wt | 292.33 |
| Solubility | DMSO : 12.5 mg/mL (42.76 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4208 mL | 17.104 mL | 34.2079 mL |
| 5 mM | 684.2 μL | 3.4208 mL | 6.8416 mL |
| 10 mM | 342.1 μL | 1.7104 mL | 3.4208 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)